Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can hospitals manufacture their own stem cells? a french trial aims to find out

NCT ID NCT07735559

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether a hospital can produce high-quality induced pluripotent stem cells (iPSCs) from blood samples taken from healthy volunteers. The goal is to create a French hospital-based platform that can generate clinical-grade stem cells for future regenerative medicine applications. Blood samples from four healthy adults will be used to create iPSC lines, which will then be checked for quality and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood collection for induced pluripotent stem cell (iPSC) generation
What this could lead to
If successful, this could establish a hospital-based platform to produce clinical-grade stem cells for future regenerative therapies.
What could go wrong
This is a very early feasibility study with only 6 participants, focused on manufacturing rather than treating disease. The stem cells may not meet quality standards.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and ≤ 35 years * No medical contraindication to a 54 mL blood sample collection * Negative viral serology for: * Human Immunodeficiency Virus (HIV) * Hepatitis B Virus (HBV) * Hepatitis C Virus (HCV) * Human T-lymphotropic Virus type 1 (HTLV-1) * A participant who agrees to have their anonymized biological samples and cell lines stored in a biological sample collection for other research purposes (including genetic research) Exclusion Criteria: * Any active medical condition * Any ongoingl treatment * Subjects who cannot read and/or write * Inability to ensure participant during the study period * Participation in another clinical trial or administration of an off-label medication that could interfere with blood test results. * Participation in another research protocol involving biological sampling that limits the number of mL to be collected. * Failure to obtain informed consent * Not enrolled in a social security program, * Subject participating in another research study with an ongoing exclusion period * Protected populations under the French Public Health Code (women who are giving birth, breastfeeding, or pregnant; subjects deprived of liberty by judicial or administrative decision; adults under legal protection (under any form of guardianship))

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Induced pluripotent stem cells (IPSC) production are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Induced pluripotent stem cells (IPSC) production Regenerative medicine

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Montpellier

    Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.